Skip to main content
Premium Trial:

Request an Annual Quote

Memorial Sloan-Kettering Receives OK from NY State to Use Sequenom's MassArray

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Memorial Sloan-Kettering Cancer Center has received what it believes is the first approval from the New York State Department of Health to use Sequenom's MassArray Compact 384 system for diagnosing gene mutations in patients.

The hospital will use the instrument to look for mutations in EGFR, KRAS, and BRAF in biopsy samples in patients with lung, colorectal, and thyroid cancers, as well as melanoma. The platform will also allow researchers at MSKCC to investigate mutations in lesser known genes and enroll patients in clinical trials for new, experimental targeted drugs.

Marc Ladanyi, chief of the Molecular Diagnostics Service and director of the Diagnostic Molecular Pathology Laboratory at MSKCC, led the team that developed the protocols and validated the Sequenom platform for clinical applications.

Ladanyi could not be reached for comment, but in MSKCC's newsletter, he said, "To our knowledge, we are the only hospital to have New York State approval to use the technology for this purpose."

At publication time, the NYS Department of Health had not confirmed that statement for GenomeWeb Daily News.

Last month, Sequenom launched the next iteration of the MassArray platform, called MassArray Analyzer 4.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.